Sunday 18 October 2026
Export NAUT’s income statement to Excel — free account
Nautilus Biotechnology, Inc.
NAUT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 8.33% and free cash flow fell 3.16%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
2.06
0.10
−4.63%
Follow NAUT
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | — | — | — |
+8 more quarters Free account |
P/S ratio |
0.00 | — | — | — | |
P/FCF ratio |
0.00 | — | — | — | |
P/Operating CF |
(17.32) | — | — | — | |
P/B ratio |
1.81 | — | — | — | |
Price to Tangible BV |
1.81 | — | — | — | |
EV/Sales |
0.00 | — | — | — | |
EV/EBITDA |
0.00 | — | — | — | |
EV/Operating CF |
(3.06) | — | — | — | |
EV/FCF |
(2.96) | — | — | — | |
Quick Ratio |
9.73 | 11.49 | 13.00 | 14.63 | |
Current Ratio |
10.14 | 11.85 | 13.33 | 14.95 | |
Net Debt/EBITDA |
5.81 | 6.51 | 7.41 | 9.28 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.95 | 0.89 | 0.90 | 0.81 | |
Capex/Depreciation |
(0.35) | (0.36) | (0.17) | (0.32) | |
Research and Development Expense of Revenue |
5,059.47% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
3,328.95% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
609.47% | 0.00% | 0.00% | 0.00% | |
Graham Net Nets |
0.23 | — | — | — | |
Graham Number |
0.00 | — | — | — | |
Earnings Yield |
(24.06%) | — | — | — | |
Free Cash Flow Yield |
(21.81%) | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.11) | (0.10) | (0.10) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.11) | (0.11) | (0.10) | (0.09) | |
Cash per Share |
0.66 | 0.76 | 0.82 | 1.04 | |
Shareholders Equity per Share |
1.03 | 1.14 | 1.24 | 1.34 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.03 | 1.14 | 1.24 | 1.34 | |
Free Cash Flow |
(14.18) | (13.61) | (12.62) | (11.45) | |
Working Capital |
78.99 | 90.49 | 98.01 | 125.34 | |
Capital Expenditures |
(0.45) | (0.51) | (0.24) | (0.42) | |
Net Current Asset Value |
55.16 | 65.47 | 71.82 | 102.55 | |
EV/EBIT |
0.00 | — | — | — | |
Capex to Sales |
2.39 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | — | — | — | |
| Other line items | |||||
Average Payables |
1.03 | 1.01 | 0.97 | 1.19 | |
Average Assets |
188.38 | 202.73 | 216.93 | 230.31 | |
Average Common Equity |
156.10 | 169.43 | 182.85 | 196.29 |
Columns are period end dates